Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the effects of eslicarbazepine acetate on cognition in comparison with placebo as
adjunctive therapy in children aged 6 to 16 years old with refractory partial-onset seizures.